全文获取类型
收费全文 | 350篇 |
免费 | 14篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 6篇 |
妇产科学 | 14篇 |
基础医学 | 49篇 |
口腔科学 | 10篇 |
临床医学 | 15篇 |
内科学 | 100篇 |
皮肤病学 | 1篇 |
神经病学 | 21篇 |
特种医学 | 11篇 |
外科学 | 14篇 |
综合类 | 2篇 |
预防医学 | 24篇 |
眼科学 | 5篇 |
药学 | 65篇 |
中国医学 | 1篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 9篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 15篇 |
2013年 | 11篇 |
2012年 | 17篇 |
2011年 | 19篇 |
2010年 | 18篇 |
2009年 | 10篇 |
2008年 | 19篇 |
2007年 | 21篇 |
2006年 | 20篇 |
2005年 | 24篇 |
2004年 | 14篇 |
2003年 | 21篇 |
2002年 | 17篇 |
2001年 | 4篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 6篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 12篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 6篇 |
1989年 | 2篇 |
1986年 | 2篇 |
1985年 | 7篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1957年 | 1篇 |
排序方式: 共有367条查询结果,搜索用时 15 毫秒
361.
Sho Shibata Sumie Tabata Hajime Morita Tomomi Endo Naoto Kawasaki Yoshio Okamoto Shojiro Inano Yoko Takiuchi Akiko Fukunaga Toshiyuki Kitano 《Internal medicine (Tokyo, Japan)》2021,60(10):1589
TAFRO syndrome and POEMS syndrome are lymphoproliferative disorders with elevated interleukin-6 and vascular endothelial growth factor (VEGF) levels; however, their underlying pathogenic mechanisms remain unclear. Similarities have been reported in the pathological findings of the lymph nodes of TAFRO syndrome, Multicentric Castleman disease (MCD), and some cases of POEMS syndrome. However, there is no consensus on the relationship among them. We encountered a case of lymphoproliferative disorder that presented with manifestations of both TAFRO syndrome and POEMS syndrome. This case may be a subtype of idiopathic MCD and will be very important for establishing the disease concept of TAFRO syndrome and POEMS syndrome. 相似文献
362.
Seto T Seki N Uematsu K Tanigaki T Shioya S Koboyashi T Umemura S Eguchi K 《Respirology (Carlton, Vic.)》2006,11(1):113-116
A 55-year-old man was treated with gefitinib for disseminated pleural lesions, 1 year after resection of the left lower lobe for non-small cell lung cancer. After 6 weeks of continuous daily treatment with oral gefitinib, he developed dyspnoea on exertion and a non-productive cough. CXR and CT revealed focal areas of ground-glass opacity (GGO) in the right upper lobe. Despite gefitinib being discontinued, high-resolution CT revealed extension of GGO and restructuring of lung parenchyma, suggesting acute interstitial pneumonia. Transbronchial biopsy revealed acute-phase diffuse alveolar damage. After administration of methylprednisolone pulse therapy (1 g/day intravenously) for three consecutive days, the areas of GGO shrank on high-resolution CT and symptoms resolved. Diffuse alveolar damage caused by gefitinib can be successfully treated in the early phase with high-dose corticosteroids. Patients receiving gefitinib should be carefully examined for symptoms and undergo CT if their condition deteriorates. 相似文献
363.
Tabata S Ohno T Tomo K Hishita T Hada S Mizumoto T Furukawa H 《[Rinshō ketsueki] The Japanese journal of clinical hematology》2003,44(5):313-317
Chronic myeloid leukemia in a 61-year-old man progressed into the accelerated phase 8 months after the initial evaluation (Ph chromosome [20/20], FISH 93.5%), although the major cytogenetic response (Ph chromosome [0/20], FISH 9.7%) had been achieved 6 months after the initiation of the treatment with interferon and hydroxyurea. The Peripheral blood stem cells (Ph chromosome [0/20], FISH 5.8%, PCR 2.7 x 10(2) copies/microgram RNA) were harvested simultaneously with the attempt to induce the second chronic phase using the mini-ICE (idarubicin, cytosine arabinoside and etoposide) therapy. However, 2 months later, the disease progressed into blast crisis with the additional chromosomal abnormalities, and did not respond to the re-induction therapy with idarubicin and cytosine arabinoside. Autologous stem cell transplantation was then performed using the preparatory regimen with busulfan and cyclophosphamide. The third chronic phase was successfully achieved, and has been well maintained with imatinib for more than 13 months (Ph chromosome [0/20], FISH 0.0%, PCR < 10(2) copies/microgram RNA). This may be a rare case in which normal hematopoietic stem cells could be enriched in the peripheral blood in the accelerated phase, and that cytogenetic remission was achieved using these cells in the blast crisis. Flexible use of peripheral blood stem cells and imatinib could be an additional strategy for the better treatment of chronic myeloid leukemia. 相似文献
364.
Shoko Nakayama Mitsuhiro Matsuda Tatsuya Adachi Sanae Sueda Yuka Ohashi Sumie Awaji 《Platelets》2019,30(5):637-645
The international prognostic index (IPI) is a broadly utilized clinical tool to aid in predicting the prognosis of patients with aggressive non-Hodgkin’s lymphomas (NHL). However, since this score was developed before the development of rituximab, and the introduction of combined rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) (R-CHOP) therapy for NHL has dramatically improved clinical outcomes, the IPI may be inadequate to assess prognosis in the R-CHOP era. In the present study, we assessed the utility of hemoglobin (Hb) level and platelet count to predict prognosis in diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), the largest category of aggressive NHL. A total of 89 patients newly diagnosed with nodal DLBCL, NOS and treated with R-CHOP therapy were included. The blood count results at diagnosis were statistically analyzed. Available biopsy specimens were immunostained for interleukin (IL)-6. Hb levels lower than 120 g/L (p = 0.0133) and platelet counts lower than 135 × 109/L (p = 0.0233) were associated with worse overall survival (OS). Based on those levels as cutoff values, a hemoglobin-platelet (HP) index was calculated by assigning 1 point for an Hb level or a platelet count lower than the cutoff. The patients were divided into three groups based on the HP index: high, with a score of 2 (n = 8); intermediate, with a score of 1 (n = 39); and low, with a score of 0 (n = 42). A higher HP index was associated with worse OS (p = 0.0055). Patients with IL-6–positive tumors had significantly lower Hb levels than those with IL-6–negative tumors (p = 0.0264), suggesting that abnormal production of IL-6 by lymphoma cells is associated with anemia. On the other hand, there was no association between the platelet counts and the IL-6 expression in the lymphoma cells. In a multivariate analysis, the HP index predicted OS rate independently of the IPI. Since the HP index is based on inexpensive and broadly available laboratory values, we believe that this index will have great utility in clinical practice, and the addition of this index to IPI could more precisely predict prognosis. 相似文献
365.
Kazunari Aoki Yuichiro Ono Sumie Tabata Akiko Matsushita Takayuki Ishikawa 《International journal of hematology》2013,97(2):272-274
The standard therapy for anti-erythropoietin (EPO) antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5–1.0 mg/kg. However, many patients with severe chronic kidney disease (CKD) and chronic heart failure cannot tolerate such an immunosuppressive regimen. An 86-year-old man with anemia related to CKD and chronic heart failure, who had received recombinant human erythropoietin subcutaneously, developed anti-EPO antibody-mediated PRCA. The patient was treated with CyA followed by PSL (1.0 mg/kg); however, he was unable to tolerate this drug regimen. The PSL dose was reduced to 0.2 mg/kg. Surprisingly, his reticulocyte count increased 3 months later, and RBC transfusion was no longer required. Low-dose PSL is a treatment option for patients with anti-EPO antibody-mediated PRCA who cannot tolerate CyA and PSL (0.5–1.0 mg/kg). 相似文献
366.
Takayuki Katsuyama Minglu Yan Sonia Zeggar Sumie Hiramatsu Yoshia Miyawaki 《Modern rheumatology / the Japan Rheumatism Association》2017,27(5):773-777
Objectives: To determine prognostic factors of methotrexate-associated lymphoproliferative disorder (MTX-LPD) and evaluate the efficacy and safety of biological therapy in rheumatoid arthritis (RA) complicated with MTX-LPD.Methods: Thirty RA patients who developed MTX-LPD were investigated in this study. We compared the clinical and laboratory parameters of patients who achieved regression of LPD by MTX withdrawal with those who required chemotherapy and evaluated the clinical course of RA after LPD development.Results: Twenty-three patients (76.7%) achieved regression of LPD by MTX withdrawal. Chemotherapy-free patients had a tendency of shorter RA duration (13.1 vs. 22.0 years, p?=?0.108) and higher doses of MTX at LPD diagnosis (8.0 vs. 5.3?mg/w, p?=?0.067) than patients who required chemotherapy. A significantly higher positive rate of peripheral blood Epstein–Barr virus (EBV)-DNA was observed in the chemotherapy-free group (9/9 vs. 0/3, p?=?0.0002). Of 15 patients that received biological agents after LPD development, 14 patients (93.3%) demonstrated an improved disease activity of RA and persistent remission of LPD, whereas only one patient experienced relapse of LPD during tocilizumab therapy.Conclusions: Peripheral blood EBV-DNA positivity is a potential prognostic marker of better outcome in MTX-LPD. Biological agents could be an option for the treatment of RA patients with MTX-LPD. 相似文献
367.
Hideki Yoshida Ko Hirano Tomomi Sato Nobutaka Mitsuda Mika Nomoto Kenichiro Maeo Eriko Koketsu Rie Mitani Mayuko Kawamura Sumie Ishiguro Yasuomi Tada Masaru Ohme-Takagi Makoto Matsuoka Miyako Ueguchi-Tanaka 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(21):7861-7866